DNA damage response companies research the cellular pathways that detect, repair and respond to damaged DNA. These mechanisms are important in cancer biology, genomic stability and the development of targeted therapeutics.
This category includes companies working on:
Browse 15 UK DNA damage response companies below.
Small molecule inhibitors targeting APOBEC enzymes in cancer
Apobec Discovery is a preclinical-stage biotechnology company developing first-in-class small molecule inhibitors of APOBEC3A and APOBEC3B, cytidine deaminase enzymes that drive…
Small molecule MMR inhibitors to enhance tumour immunogenicity
NeoPhore is a UK immuno-oncology company developing first-in-class small molecule inhibitors of the DNA mismatch repair pathway. By transiently blocking MMR, the company's…
Clinical-stage biopharma improving nucleoside analogue chemotherapy efficacy
NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry. Its approach transforms…
Precision oncology biotech targeting synthetic lethality in cancer
Tessellate Bio is a precision oncology company developing small molecule drugs that exploit synthetic lethality, the principle that certain genetic vulnerabilities in cancer cells…
Integrated drug discovery CRO from target to clinical candidate
Sygnature Discovery is a UK-headquartered integrated drug discovery contract research organisation. Operating from sites in Nottingham, Alderley Park, and Glasgow, the company…
Sperm DNA fragmentation diagnostics for male fertility assessment
Examen is a Belfast-based diagnostics company specialising in male reproductive health. Its proprietary assay-based technology measures single-strand and double-strand sperm DNA…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline…
Precision oncology biotech targeting novel DNA damage response pathways
Nodus Oncology is a preclinical-stage biotechnology company developing small molecule inhibitors against novel DNA damage response targets for molecularly defined cancer patient…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation…
Small molecule inhibitors targeting somatic expansion in neurodegeneration
LoQus23 Therapeutics is a biotechnology company developing oral small molecule inhibitors of DNA mismatch repair for the treatment of Huntington's disease and other triplet repeat…
First-in-class small molecule therapeutics targeting DNA uracilation in cancer
CV6 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule drugs for cancer and inflammatory diseases. Its lead asset CV6-168 is a…
Academic cancer research institute and drug discoverer
The Institute of Cancer Research (ICR) is an independent research institute and member institution of the University of London, specialising in cancer biology, drug discovery,…